Bristol-Myers Squibb Company (BMY)
NYSE: BMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BMY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $121.95B
- P/E (TTM)
- 13.15
- Forward P/E
- 9.06
- EPS (TTM)
- $4.54
- Dividend yield
- 4.20% ($2.51)
- Ex-dividend date
- Oct 2, 2026
- 52-week range
- 42.52 – 68.64
- Day range
- 59.01 – 60.10
- Volume / Avg
- 11.04M / 11.17M
- Beta
- —
- Shares outstanding
- 2.04B
- Next earnings
- Oct 29, 2026
52-week range
BMY stock today
Bristol-Myers Squibb (BMY) closed at $59.70 on Oct 7, up 0.18% (+$0.11), versus the S&P 500's 0.22% decline. At this level, BMY sits in the middle of its 52-week range of $42.52 to $68.64: 13.0% below the high, set on Aug 19, 2026 and 40.4% above the low. BMY is up 10.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 33.7%.
At 13.1x trailing earnings, Bristol-Myers Squibb trades below the peer-group median of 21.2x. Its forward P/E of 9.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Bristol-Myers Squibb's next earnings report is expected on Oct 29, 2026. Bristol-Myers Squibb pays an annual dividend of $2.51 per share, a 4.20% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Bristol-Myers Squibb
Company profileBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christopher S. Boerner Ph.D.
- Headquarters
- Princeton, NJ
- Employees
- 32,500
- Website
- bms.com
Financial highlights
Full financialsIn fiscal 2025, Bristol-Myers Squibb generated $48.19 billion in revenue, down 0.2% from fiscal 2024, its first annual decline since 2023. Net income was $7.05 billion, for a net margin of 14.6% versus a median of 13.7% in the prior 5 years. Gross margin was 71.1% (flat year over year).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Growth | -0.22% | +7.32% | -2.50% | -0.49% | +9.09% |
| Net income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| EPS (diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Analyst forecast
ForecastConsensus (28 analysts)
hold
Avg. price target
$66.17+10.84%
- Strong buy 3
- Buy 6
- Hold 18
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $1.68
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $1.62 vs —
Dividends
Dividend history- Annual dividend
- $2.51
- Dividend yield
- 4.20%
- Last payment
- $0.63
- Ex-dividend date
- Oct 2, 2026
BMY news
All BMY news- 2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)NasdaqBMY, O
- Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An OpportunitySeeking Alpha
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?NasdaqBMY, GERN, KROS
- Can Redwire's Microgravity Pharma Work Create New Revenue Streams?NasdaqRDW, BMY, LLY
- Here's Why Bristol Myers Squibb (BMY) is a Strong Value StockNasdaq
- Bristol-Myers Squibb: Patent Cliff Is Still A ProblemSeeking Alpha
- Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASANasdaqBMY, DG, EQNR
- Relative Strength Alert For Bristol Myers SquibbNasdaq
Bristol-Myers Squibb peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Incorporated | 505.64 | +0.66% | $128.16B | vs BMY |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs BMY |
| GSKGSK plc ADR | 47.02 | +0.90% | $94.21B | vs BMY |
| PFEPfizer Inc. | 28.00 | +1.82% | $159.59B | vs BMY |
| REGNRegeneron Pharmaceuticals Inc. | 742.12 | +0.46% | $76.40B | vs BMY |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs BMY |
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs BMY |
| TAKTakeda Pharmaceutical Company Limited ADR | 18.37 | +1.49% | $58.68B | vs BMY |
Indexes, lists and sector
Index membership
Appears in lists
Bristol-Myers Squibb stock FAQ
What is Bristol-Myers Squibb's stock price today?
BMY last traded at $59.70 as of Oct 7, 4:00 PM EDT, up 0.18% on the day. Prices are delayed at least 15 minutes.
Does Bristol-Myers Squibb pay a dividend?
Yes. Bristol-Myers Squibb pays $2.51 per share annually, a 4.20% yield. The most recent dividend of $0.63 had an ex-dividend date of Oct 2, 2026.
When is Bristol-Myers Squibb's next earnings date?
Bristol-Myers Squibb is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $1.68.
What is BMY's P/E ratio?
BMY trades at a trailing P/E ratio of 13.15 and a forward P/E of 9.06, compared with a median of 21.2 for its closest peers.
Is Bristol-Myers Squibb in the S&P 500?
Yes. Bristol-Myers Squibb (BMY) is a constituent of the S&P 500 index.
Who is Bristol-Myers Squibb's CEO?
Dr. Christopher S. Boerner Ph.D. is the chief executive officer of Bristol-Myers Squibb Company, which has about 32,500 employees.
What is the BMY 52-week high?
The 52-week high for BMY is $68.64 and the 52-week low is $42.52. The stock is currently 13.0% below its high.